Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             67 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Acknowledgement to Reviewers 2012
4 p. I-
1 p.
artikel
2 Aggressive relapsing multiple sclerosis characterized by rapid disability progression Scott, Thomas F.
2013
4 p. 370-376
7 p.
artikel
3 An agent-based simulation model for informed shared decision making in multiple sclerosis Veloso, Mário
2013
4 p. 377-384
8 p.
artikel
4 A retrospective review of lithium usage in veterans with multiple sclerosis Rinker II, John R.
2013
4 p. 327-333
7 p.
artikel
5 Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients Basnyat, Pabitra
2015
4 p. 334-338
5 p.
artikel
6 Association of vitamin D deficiency with RNFL thickness in MS individuals without history of optic neuritis Fjeldstad, Cecilie
2014
4 p. 489-493
5 p.
artikel
7 Can white matter changes occur in disorders of peripheral nerve hyperexcitability? Sedarous, Mary
2013
4 p. 388-390
3 p.
artikel
8 Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables Vuletic, Simona
2014
4 p. 533-541
9 p.
artikel
9 Chronic cerebrospinal venous insufficiency is unlikely to be a direct trigger of multiple sclerosis Simka, Marian
2013
4 p. 334-339
6 p.
artikel
10 Clinical decision-making in multiple sclerosis: Challenges reported internationally with emerging treatment complexity Ng, Pamela
2015
4 p. 320-328
9 p.
artikel
11 CLIPPERS syndrome: Case report in a Brazilian patient with a long term disease evolution Marinho, Patricia Beatriz Christino
2015
4 p. 311-314
4 p.
artikel
12 Cognitive impact of anticholinergic medication in MS: Adding insult to injury? Cruce, Roxana
2012
4 p. 156-161
6 p.
artikel
13 Cognitive impairment in multiple sclerosis: An 18 year follow-up study Strober, Lauren B.
2014
4 p. 473-481
9 p.
artikel
14 Cognitive performance profile in different phenotypes of MS with cognitive complaints Rosti-Otajärvi, Eija
2014
4 p. 463-472
10 p.
artikel
15 Computerized cognitive testing for patients with multiple sclerosis Lapshin, Helen
2012
4 p. 196-201
6 p.
artikel
16 Corrigendum to “Cardiovascular autonomic dysfunction in multiple sclerosis: A meta-analysis” [Mult. Scler. Relat. Disord. 4 (2015) 104–111] Racosta, Juan Manuel
2015
4 p. 385-
1 p.
artikel
17 Deep brain stimulation and multiple sclerosis: Therapeutic applications Roy, Holly A.
2014
4 p. 431-439
9 p.
artikel
18 Does natalizumab treatment increase the risk of herpes simplex encephalitis in multiple sclerosis? Case and discussion Sharma, Kanchan
2013
4 p. 385-387
3 p.
artikel
19 Editors’ Welcome Banwell, Brenda
2015
4 p. A1-A3
nvt p.
artikel
20 Editors' welcome Banwell, Brenda
2012
4 p. 153-
1 p.
artikel
21 Editors׳ welcome Banwell, Brenda
2014
4 p. 417-418
2 p.
artikel
22 Effectiveness of telerehabilitation interventions in persons with multiple sclerosis: A systematic review Amatya, B.
2015
4 p. 358-369
12 p.
artikel
23 Effects of dimethyl fumarate on lymphocyte subsets Berkovich, Regina
2015
4 p. 339-341
3 p.
artikel
24 Fatigue is associated with metabolic and density alterations of cortical and deep gray matter in Relapsing-Remitting-Multiple Sclerosis patients at the earlier stage of the disease: A PET/MR study Derache, Nathalie
2013
4 p. 362-369
8 p.
artikel
25 Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings Kappos, Ludwig
2014
4 p. 494-504
11 p.
artikel
26 Genetic and environmental backgrounds responsible for the changes in the phenotype of MS in Japanese subjects Kira, Jun-ichi
2012
4 p. 188-195
8 p.
artikel
27 GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis Wolinsky, Jerry S.
2015
4 p. 370-376
7 p.
artikel
28 Health care utilization before and after intensive care unit admission in multiple sclerosis Marrie, Ruth Ann
2015
4 p. 296-303
8 p.
artikel
29 HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis Dhib-Jalbut, Suhayl
2013
4 p. 340-348
9 p.
artikel
30 Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis Newsome, S.D.
2015
4 p. 350-357
8 p.
artikel
31 Impaired recognition of emotional facial expressions in patients with multiple sclerosis Berneiser, Julia
2014
4 p. 482-488
7 p.
artikel
32 Improvement of multiple sclerosis-associated tremor as a treatment effect of natalizumab Rinker II, John R.
2014
4 p. 505-512
8 p.
artikel
33 Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Giovannoni, Gavin
2015
4 p. 329-333
5 p.
artikel
34 Late onset multiple sclerosis: Is it really late onset? Roohani, Pezhman
2014
4 p. 444-449
6 p.
artikel
35 Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients Sangalli, Francesca
2014
4 p. 520-526
7 p.
artikel
36 Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel Phillips, J. Theodore
2014
4 p. 513-519
7 p.
artikel
37 MRI characteristics of periaqueductal lesions in multiple sclerosis Papadopoulou, Athina
2014
4 p. 542-551
10 p.
artikel
38 Multiple Cranial Neuropathy (A Teaching Case) Toro, Jaime
2013
4 p. 395-398
4 p.
artikel
39 Muscular dystrophy in a patient with multiple sclerosis. Another “double-trouble”? Parissis, Dimitrios
2015
4 p. 342-344
3 p.
artikel
40 Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment Barroso, Bruno
2015
4 p. 380-382
3 p.
artikel
41 Neurologists׳ accuracy in predicting cognitive impairment in multiple sclerosis Romero, Kristoffer
2015
4 p. 291-295
5 p.
artikel
42 Neuroprotection for acute optic neuritis—Can it work? Raftopoulos, R.E.
2013
4 p. 307-311
5 p.
artikel
43 Nose to brain: Is the trigeminal nerve a conduit for CNS disease? Gay, Frederick
2012
4 p. 154-155
2 p.
artikel
44 Occupational stress and personality traits in multiple sclerosis: A preliminary study Concetta Incerti, Chiara
2015
4 p. 315-319
5 p.
artikel
45 Pathologic yawning in neuromyelitis optica spectrum disorders Lana-Peixoto, Marco A.
2014
4 p. 527-532
6 p.
artikel
46 Persistence of the effects of attention and executive functions intensive rehabilitation in relapsing remitting multiple sclerosis Mattioli, F.
2012
4 p. 168-173
6 p.
artikel
47 Potential therapeutic mechanism of K+ channel block for MS Baker, Mark D.
2013
4 p. 270-280
11 p.
artikel
48 Presentation of neuromyelitis optica spectrum disorder after more than twenty years of systemic sclerosis Hernández, Zulma M.
2012
4 p. 202-203
2 p.
artikel
49 Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study Marrie, Ruth Ann
2013
4 p. 355-361
7 p.
artikel
50 Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice Carruthers, Robert L.
2014
4 p. 419-430
12 p.
artikel
51 Promoting regeneration and repair in Multiple Sclerosis Banwell, B.
2013
4 p. 261-262
2 p.
artikel
52 Promoting return of function in multiple sclerosis: An integrated approach Gacias, Mar
2013
4 p. 312-326
15 p.
artikel
53 Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosis Chahin, Salim
2015
4 p. 304-310
7 p.
artikel
54 Review of animal models of neuromyelitis optica Jones, Melina V.
2012
4 p. 174-179
6 p.
artikel
55 Sodium imaging as a marker of tissue injury in patients with multiple sclerosis Inglese, M.
2013
4 p. 263-269
7 p.
artikel
56 Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: A meta-analysis Ruiz-Gaviria, Rafael
2015
4 p. 345-349
5 p.
artikel
57 The case for vitamin D supplementation in multiple sclerosis Ganesh, Aravind
2013
4 p. 281-306
26 p.
artikel
58 The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk Khatri, Bhupendra O.
2015
4 p. 377-379
3 p.
artikel
59 The effect of menarche age, parity and lactation on bone mineral density in premenopausal ambulatory multiple sclerosis patients Sioka, Chrissa
2015
4 p. 287-290
4 p.
artikel
60 The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study Marrie, Ruth Ann
2012
4 p. 162-167
6 p.
artikel
61 The UK patient experience of relapse in Multiple Sclerosis treated with first disease modifying therapies Duddy, Martin
2014
4 p. 450-456
7 p.
artikel
62 Treatment of neuromyelitis optica: Review and recommendations Kimbrough, Dorlan J.
2012
4 p. 180-187
8 p.
artikel
63 Varicella vaccination after fingolimod: A case report Berger, Joseph R.
2013
4 p. 391-394
4 p.
artikel
64 Walking for six minutes increases both simple reaction time and stepping reaction time in moderately disabled people with Multiple Sclerosis Barr, Christopher
2014
4 p. 457-462
6 p.
artikel
65 Web search behavior for multiple sclerosis: An infodemiological study Brigo, Francesco
2014
4 p. 440-443
4 p.
artikel
66 White matter relapsing remitting disease: “Susac’s syndrome”—An underdiagnosed entity Schottlaender, Lucia V.
2013
4 p. 349-354
6 p.
artikel
67 Why some of us do not like the expression “no evidence of disease activity” (NEDA) in multiple sclerosis Dadalti Fragoso, Yara
2015
4 p. 383-384
2 p.
artikel
                             67 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland